Open AccessEfficacy and Safety of First-Line Therapies in EGFR -Mutated Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Author(s) -
Katrin Haeussler,
Xuan Wang,
Katherine B. Winfree,
Yulia Dyachkova,
S Traoré,
Tarun Puri,
Howard Thom,
C. Papagiannopoulos,
Maria Nassim,
Kaisa Taipale
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0885
Subject(s) - erlotinib , ramucirumab , medicine , osimertinib , gefitinib , oncology , lung cancer , randomized controlled trial , clinical trial , cabozantinib , epidermal growth factor receptor , cancer
Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive ( EGFRm+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. Results: For progression-free survival, ramucirumab + erlotinib was comparable to osimertinib and dacomitinib in the primary analysis. Conclusion: The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm + advanced NSCLC. Registration information: PROSPERO ID: CRD42020136247
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom